The Regulatory and Sourcing Reality BPC-157 is not FDA-approved for any therapeutic use
Previous chromoendoscopy for dysplasia surveillance showed a large number of pseudopolyps extending throughout the descending and sigmoid colon
BPC-157 accelerates ligament remodeling by: Increasing fibroblast density in the ligament substance Enhancing collagen cross-linking for greater tensile strength Reducing the duration of protective splinting/bracing Muscle Strains and Tears Acute muscle injuries (hamstring strains, quadriceps tears, calf strains) benefit from early BPC-157 intervention
In my clinical experience, patients with tendinopathy lasting 6-24 months often report: Significant pain reduction by week 2-3 Improved load tolerance during physical therapy by week 4-6 Return to prior activity levels (with appropriate rehab) by week 10-14 Ligament Injuries Partial ligament tears (ankle sprains, knee MCL/LCL sprains, wrist sprains) often leave residual instability and chronic pain
Translation to oral administration or to human physiology is unknown
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
